Pulse Biosciences, Inc (PLSE) Stock Analysis

Q: What is the PLSE stock price target?

Take-profit $25.50 (+2.2% upside). Prior stop was $23.20.

Q: What are the risks of investing in PLSE?

Target reached (2.2% upside); Quality below floor (2.1 < 4.0); Target reached (2.2% upside); Quality below floor (2.1 < 4.0).

Q: Is PLSE overvalued or undervalued?

Pulse Biosciences, Inc trades at a P/E of N/A (forward -28.4). TrendMatrix value score: 5.0/10. Overall verdict: Sell.

Q: What do analysts say about PLSE?

8 analysts cover PLSE with a consensus score of 4.3/5. Average price target: $30.

Q: What does Pulse Biosciences, Inc do?

Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial fibrillation treatment (cardiac surgical clamp with IDE approved; cardiac catheter IDE approved December 2025) and soft tissue ablation (Vybrance percutaneous electrode with 510(k) clearance). The company has minimal revenue; it began the PRECISE BTN thyroid clinical trial in September 2025 and received cardiac surgical IDE approval in September 2025.

Breakout setup

SellModerate ConfidenceUpdated 8 hr ago (May 20, 2026, 8:01 AM ET)

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $24.97: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 16%; Below-average business quality.

$24.97+2.2% A.UpsideScore 5.0/10#20 of 25 Medical Instruments & Supplies

QualityF-score4 / 9FCF yield-1.68%

Stop $23.20Target $25.50(analyst − 15%)A.R:R 0.1:1

Analyst target$30.00+20.1%2 analysts

Range unavailable (2 analysts)

Passes 6/8 gates (positive momentum, no SEC red flags, news events none recent, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity. Suitability: aggressive.

Recent Developments — Pulse Biosciences, Inc

Latest news

Pulse Biosciences Co‑Chairmen, CEO Purchase ~$13.3M In Shares Via ATM Program — benzinga May 12, 2026 positive
Earnings Scheduled For May 4, 2026 — benzinga May 4, 2026 neutral
Reported Saturday, Pulse Biosciences' nPulse Cardiac Catheter System Delivers 90% Kaplan-Meier Freedom From AF At One Ye — benzinga Apr 27, 2026 positive
Pulse Biosciences Appoints Liane Teplitsky As Chief Operating Officer And Dr. David Kenigsberg As Chief Medical Officer — benzinga Apr 9, 2026 neutral
12 Health Care Stocks Moving In Tuesday's Intraday Session — benzinga Apr 7, 2026 neutral

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards

No bull case signals

Risks

Target reached (2.2% upside)

Quality below floor (2.1 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-28.4

Mkt Cap$1.7B

EV/EBITDA-21.8

Profit Mgn0.0%

ROE-80.7%

Rev Growth—

Beta1.63

DividendNone

Rating analysts8

Quality Signals

Piotroski F4/9

Options Flow

P/C1.20bearish

IV72%elevated

Max Pain$17-31.9% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.015%0.75

Quality2.115%0.32

Growth5.015%0.75

Momentum7.710%0.77

Sentiment6.510%0.65

Insider Activity7.410%0.74

Peer Rank3.910%0.39

Technical Setup4.85%0.24

Risk Profile3.25%0.16

Catalyst4.05%0.20

Overall (Σ contributions)4.97

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Moat

4.8

Current Ratio

5.7

Cash-burning: FCF -3872% of revenueNo competitive moatQuality concerns

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank

0.4

Value Rank

5.0

Growth Rank

5.0

GatesA.R:R 0.1 < 1.5@spotINSIDER 1.54%=EXTREMEMomentum 7.7>=5.5No SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 86d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARBreakoutSuitability: Aggressive

RSI

64 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $18.36Resistance $27.98

Price Targets

$23

$26

A.Upside+2.1%

A.R:R0.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Target reached (2.2% upside)

! Quality below floor (2.1 < 4.0)

! Reward/Risk 0.1:1 at current price — below 1.5:1 minimum

Earnings

2/4 beats

Next Earnings2026-08-14 (86d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is PLSE stock a buy right now?

Sell if holding. Engine safety override at $24.97: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.0/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 64, MACD bullish. Prior stop was $23.20. Score 5.0/10, moderate confidence.

What is the PLSE stock price target?

Take-profit target: $25.50 (+2.2% upside). Prior stop was $23.20. Stop-loss: $23.20.

What are the risks of investing in PLSE?

Target reached (2.2% upside); Quality below floor (2.1 < 4.0).

Is PLSE overvalued or undervalued?

Pulse Biosciences, Inc trades at a P/E of N/A (forward -28.4). TrendMatrix value score: 5.0/10. Verdict: Sell.

What do analysts say about PLSE?

8 analysts cover PLSE with a consensus score of 4.3/5. Average price target: $30.

What does Pulse Biosciences, Inc do?Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial...

Pulse Biosciences develops nanosecond Pulsed-Field Ablation (nsPFA) technology via its nPulse System, targeting atrial fibrillation treatment (cardiac surgical clamp with IDE approved; cardiac catheter IDE approved December 2025) and soft tissue ablation (Vybrance percutaneous electrode with 510(k) clearance). The company has minimal revenue; it began the PRECISE BTN thyroid clinical trial in September 2025 and received cardiac surgical IDE approval in September 2025.